Ketamine is under clinical development by Freedom Biosciences and currently in Phase II for Depression. According to GlobalData, Phase II drugs for Depression have a 43% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ketamine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FREE-001 is under development for the treatment of depression. It is a ketamine-specific program, which acts by targeting N-methyl-D-aspartate (NMDA) receptor.
Freedom Biosciences overview
Freedom Biosciences is a biotechnology company engaged in developing psychedelic therapeutics. Freedom Biosciences is headquartered in San Francisco, California, the US.
For a complete picture of Ketamine’s drug-specific PTSR and LoA scores, buy the report here.